Wijnsma, Kioa Lente http://orcid.org/0000-0003-0019-109X
ter Heine, Rob
Moes, Dirk Jan A. R.
Langemeijer, Saskia
Schols, Saskia E. M.
Volokhina, Elena. B.
van den Heuvel, Lambertus P.
Wetzels, Jack F. M.
van de Kar, Nicole C. A. J.
Brüggemann, Roger J.
Funding for this research was provided by:
ZonMw (836031008)
Nierstichting (13OI116)
Article History
First Online: 13 February 2019
Compliance with Ethical Standards
:
: This work was supported by grants from ZonMw ‘Goed Gebruik Geneesmiddelen’ (Project number 836031008) and the Dutch Kidney Foundation (13OI116). These organizations did not have any role in drafting this manuscript or the decision to submit the manuscript for publication.
: Dr. Nicole C.A.J. van de Kar and Prof. Dr. Jack F.M. Wetzels are both members of the international advisory board of Alexion, and Prof. Dr. Jack F.M. Wetzels also received a grant from Alexion. Roger J. Brüggemann has served as a consultant to Astellas Pharma, Inc., F2G, Gilead Sciences, Merck Sharpe and Dome Corp., and Pfizer, Inc., and has received unrestricted research grants from Astellas Pharma, Inc., Gilead Sciences, Merck Sharpe and Dome Corp., and Pfizer, Inc. All contracts were through Radboud University Medical Center (Radboudumc) and all payments were invoiced by Radboudumc. Kioa L. Wijnsma, Rob ter Heine, Dirk Jan A.R Moes, Saskia Langemeijer, Saskia E.M. Schols, Elena B. Volokhina and Lambertus P. van den Heuvel have no conflict of interest.